Quest Diagnostics Aktie News

Diagnostic testing and information services provider Quest Diagnostics (DGX 7.04%) reported fiscal 2025 second-quarter results on Tuesday, July 22, that topped analysts' consensus expectations. Q2 revenue hit $2.76 billion and adjusted earnings per share (EPS) came in at $2.62.

Quest Diagnostics (DGX 7.16%) reported its second-quarter 2025 results on July 22, achieving consolidated revenue of $2.76 billion (up 15.2% year over year), organic revenue growth of 5.2%, while adjusted EPS rose 11.5% year over year to $2.62. Management raised full-year revenue guidance to $10.8 billion to $10.92 billion and adjusted EPS to $9.63 to $9.83, citing sustained demand for advanced...

Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2025 Earnings Conference Call July 22, 2025 8:30 AM ET Company Participants James E. Davis - Chairman, CEO & President Sam A.

Laboratory operator Quest Diagnostics raised its 2025 profit and revenue forecasts on Tuesday, banking on robust demand for its diagnostic tests, sending the company's shares up over 3% in premarket trade.

Second quarter revenues of $2.76 billion, up 15.2% from 2024 Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024 Year-to-date cash provided by operations of $858 million, up 67.1% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.60 and $8.80; and adjusted diluted EPS is expected...

Diagnostic testing for emerging infectious disease associated with severe neurological affects SECAUCUS, N.J. , July 15, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new diagnostic laboratory test for the Oropouche virus, an emerging disease that is increasingly found in South and Central America and the Caribbean.

For my initial rating of Quest Diagnostics (DGX), I'm calling it a buy. Forecasts point to continuing demand for diagnostic testing, while the company also grew its business via acquisitions and new solutions. Strong profit margins, proven cashflow and dividend growth, and investment-grade credit ratings from major agencies are additional upside factors.

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J. , July 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory test...